Cellmid Limited

Cellmid is an Australian biotechnology company developing innovative new therapies and diagnostic tests for heart attack, inflammatory diseases and cancer.

Cellmid holds the largest and most comprehensive portfolio of intellectual property related to midkine and midkine antagonists globally.

Midkine is a cytokine that promotes cell migration, growth and survival. Discovered over twenty years ago, midkine’s roles in inflammation and cell survival have been extensively validated by researchers worldwide.

Elevated midkine concentration in the blood or other body fluids is strongly indicative of cancer. Cellmid’s first product is a blood test that sensitively and accurately measures serum midkine levels. As well as developing this test in-house, Cellmid is actively out-licensing its broad diagnostic patent portfolio for the early detection, monitoring, prognosis and disease monitoring of cancer.

The Company’s most advanced clinical development program targets the treatment of heart attack (acute myocardial infarction or AMI) utilising the midkine protein and its anti-apoptotic characteristics.

Cellmid is also humanising its lead anti-midkine antibody for the treatment of inflammatory and autoimmune disorders.

Email Alerts for:
ASX:CDY

Latest Media Releases

Cellmid Ltd, Interim Financial Report

The directors submit the interim consolidated financial report of Cellmid Limited and Controlled Entities ("the Consolidated Entity") for the half-year ended 31 December 2013. …

Cellmid Ltd, USA RNA/DNA Patent for Surgical Adhesion Allowed

- Patent for the treatment of surgical adhesions via midkine targeting by nucleotide based drugs allowed in the US; - Comprehensive protection over antibodies, DNA/RNA antisense and…

Cellmid Ltd, Chinese Distribution Agreement Signed for Hair Loss Products

- Chinese distribution agreement signed with Beijing based company; - Cellmid’s products are expected to be sold from February 2014; - Three year exclusivity is subj…

Latest News

US threatens more tariffs: Aus shares close 0.7% lower

11 Jul 2018 - The ASX has recorded its worst performance in a month, this comes under threats from the US to impose more tariffs on Chinese goods – that could be up to $200 million…

Cellmid’s Evolis products to sell in Neiman Marcus and Bloomingdales

11 Jul 2018 - Life sciences company, Cellmid (ASX:CDY) has today announced that its Evolis anti-aging hair products will be sold permanently in Neiman Marcus and Bloomingdales stor…

Cellmid takes hair loss product to the US

20 Jul 2016 - Life sciences company, Cellmid Ltd (ASX:CDY) enters distribution partnership for US launch of its ‘evolis’ hair loss products.

Outlook: ASX to lift ahead of jobs data

16 Apr 2015 - ASX to lift ahead of jobs data. Mineral sands producer Iluka Resources Limited (ASX:ILU) inks a deal with mineral explorer Windward Resources Limited (ASX:WIN).

Midday: Aus shares rally 1.2%

21 Jan 2015 - Aus shares rally 1.2%. Western Areas Limited (ASX:WSA) reports a half year unit cash cost of $2.37/lb, about 20% lower than full year guidance.

Midday: ASX financial falls offset mining gains

17 Nov 2014 - Financial falls offset mining gains. Virgin Australia Holdings Limited’s (ASX:VAH) frequent flyer program enters into a new partnership with fuel retailer BP.

Midday: Aus shares shrug off US fiscal fears

03 Oct 2013 - Aus shares shrug off US fiscal fears. Shares in Iluka Resources Limited (ASX:ILU) lift after acquiring a tenement in Sri Lanka understood to contain a large mineral s…

Midday: Aus shares pull back from highs

20 Sep 2013 - Aus shares pull back from highs. Sydney Airport Limited (ASX:SYD) posts a rise in passenger growth, driven by more international visitors.

Midday: Aus shares jump 1.4%

18 Apr 2012 - Aus shares jump 1.4%. Shares in Grange Resources Limited (ASX:GRR) lift after posting a 64 per cent increase in production at its Savage River mine in Tasmania.